Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Molecular Partners Ag (MOLN) EBT Margin: 2020-2025

Historic EBT Margin for Molecular Partners Ag (MOLN) over the last 5 years, with Sep 2025 value amounting to -7,538.85%.

  • Molecular Partners Ag's EBT Margin fell 513004.00% to -7,538.85% in Q3 2025 from the same period last year, while for Sep 2025 it was -872.02%, marking a year-over-year increase of 2509.00%. This contributed to the annual value of -1,087.34% for FY2024, which is 20664.00% down from last year.
  • As of Q3 2025, Molecular Partners Ag's EBT Margin stood at -7,538.85%, which was down 1,193.93% from -582.63% recorded in Q2 2025.
  • In the past 5 years, Molecular Partners Ag's EBT Margin ranged from a high of 88.62% in Q1 2022 and a low of -7,538.85% during Q3 2025.
  • For the 3-year period, Molecular Partners Ag's EBT Margin averaged around -1,832.12%, with its median value being -972.40% (2024).
  • Per our database at Business Quant, Molecular Partners Ag's EBT Margin tumbled by 616,925bps in 2021 and then soared by 287,988bps in 2024.
  • Molecular Partners Ag's EBT Margin (Quarterly) stood at -348.40% in 2021, then tumbled by 21,514bps to 62.15% in 2022, then plummeted by 94,301bps to -880.86% in 2023, then slumped by 20,671bps to -1,087.57% in 2024, then slumped by 513,004bps to -7,538.85% in 2025.
  • Its EBT Margin was -7,538.85% in Q3 2025, compared to -582.63% in Q2 2025 and -1,481.63% in Q1 2025.